Oliver Rinner is co-founder and CEO of Biognosys, a Swiss proteomics technology company. He spun off the company in 2008 from the lab of Prof. Ruedi Aebersold at the ETH Zurich where he co-invented the basic technology for next-generation proteomics, which Biognosys applies today for large scale protein sequencing in clinical samples. Over the last 11 years Oliver raised several rounds of financing from institutional and corporate investors to develop the technology further with the goal to enable deep protein-level data acquisition for data-driven medicine. Oliver graduated from the University of Tubingen with a Master in Psychology and Biochemistry. He received his Ph.D. from the ETH Zurich for his work in behavioral molecular genetics.
The digitalization of healthcare is underway but not so obvious, partly because the industry has been slower than other sectors to utilize the technology. With rising life expectancies and the increasing occurrence of chronic diseases such as cancer or cardiovascular conditions, the healthcare universe is in dire need of the improvements. Digitalization will enable this progress in terms of saving costs, improved diagnostics, more effective treatment decisions, and an enhanced, holistic picture of every single patient. In addition, the global shortage of doctors, nurses and technicians demands for improved efficiency and the need for technology to help bridge the demand-supply gap in services.